Monte Rosa Therapeutics
Price & Volume
Stats
See moreOpen | $17.97 |
Previous Close | $17.55 |
Day Range | $17.50-$18.10 |
52W Range | $3.51-$25.77 |
Market Cap | $1.3B |
Shares Short | 13M |
Financials
See moreRevenue (12 Mos) | $123.6M |
Revenue Growth (YoY) | -95.4% |
Gross Profit (12 Mos) | -$10M |
Diluted EPS | -$0.46 |
News
See moreYahoo Finance • 24 days ago
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story
Yahoo Finance • 29 days ago
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Yahoo Finance • 5 months ago
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
Yahoo Finance • 5 months ago
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
About
CEO | Dr. Markus Warmuth M.D. |
Address | 321 Harrison Avenue, Boston, MA, United States, 02118 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 150 |
